Hit to lead
Hit to lead also known as lead generation is a stage in early drug discovery where small molecule hits from a high throughput screen are evaluated and undergo limited optimization to identify promising lead compounds. These lead compounds undergo more extensive optimization in a subsequent step of drug discovery called lead optimization. The drug discovery process generally follows the following path that includes a hit to lead stage:
- Target validation → Assay development → High-throughput screening → Hit to lead → Lead optimization → Preclinical development → Clinical development
On average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug.
Hit confirmation
After hits are identified from a high throughput screen, the hits are confirmed and evaluated using the following methods:- Confirmatory testing: compounds that were found active against the selected target are re-tested using the same assay conditions used during the HTS to make sure that the activity is reproducible.
- Dose response curve: the compound is tested over a range of concentrations to determine the concentration that results in half maximal binding or activity.
- Orthogonal testing: confirmed hits are assayed using a different assay which is usually closer to the target physiological condition or using a different technology.
- Secondary screening: confirmed hits are tested in a functional cellular assay to determine efficacy.
- Synthetic tractability: medicinal chemists evaluate compounds according to their synthesis feasibility and other parameters such as up-scaling or cost of goods.
- Biophysical testing: nuclear magnetic resonance, isothermal titration calorimetry, dynamic light scattering, surface plasmon resonance, dual polarisation interferometry, microscale thermophoresis are commonly used to assess whether the compound binds effectively to the target, the kinetics, thermodynamics, and stoichiometry of binding, any associated conformational change and to rule out promiscuous binding.
- Hit ranking and clustering: Confirmed hit compounds are then ranked according to the various hit confirmation experiments.
- Freedom to operate evaluation: hit structures are checked in specialized databases to determine if they are patentable.
Hit expansion
- high affinity towards the target
- selectivity versus other targets
- significant efficacy in a cellular assay
- druglikeness. Affinity, molecular weight and lipophilicity can be linked in single parameter such as ligand efficiency and lipophilic efficiency.
- low to moderate binding to human serum albumin
- low interference with P450 enzymes and P-glycoproteins
- low cytotoxicity
- metabolic stability
- high cell membrane permeability
- sufficient water solubility
- chemical stability
- synthetic tractability
- patentability
Lead optimization phase
The objective of this drug discovery phase is to synthesize lead compounds, new analogs with improved potency, reduced off-target activities, and physiochemical/metabolic properties suggestive of reasonable in vivo pharmacokinetics. This optimization is accomplished through chemical modification of the hit structure, with modifications chosen by employing knowledge of the structure–activity relationship as well as structure-based design if structural information about the target is available.Lead optimization is concerned with experimental testing and confirmation of the compound based on animal efficacy models and ADMET tools that may be followed by target identification and target validation.